亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

浙江臺州市保隆化工有限公司  

抗腫瘤產品,醋酸格拉替雷

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:董女士
  • 電話:86-0576-88702852
  • 郵件:eric@bolonpharm.com
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 硝酸舍他康唑99592-39-9
硝酸舍他康唑99592-39-9
單價 面議對比
詢價 暫無
發貨 浙江付款后3天內
過期 長期有效
更新 2014-03-12 14:28
 
詳細信息

中文名稱:

硝酸舍他康唑

中文同義詞:

1-(2-((7-氯苯并(b)噻吩-3-)甲氧基)-2-(2,4-二氯苯基)乙基)-1H-咪唑硝酸鹽;硝酸舍他康唑

英文名稱:

Sertaconazole nitrate

英文同義詞:

NITRATE SERTACONAZOLE;1-(2-((7-Chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole mononitrate;Sertaconazole nitrate;SEROTONIN;1-[2-[(7-Chlorobenzo[b]thien-3-yl)Methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-iMidazole Nitrate;DerMovit;Ertaczo;Sertaconazole Mononitrate

CAS:

99592-39-9

分子式:

C20H15Cl3N2OS.HNO3

分子量:

500.78

EINECS:

 

Mol文件:

99592-39-9.mol

©2025 浙江臺州市保隆化工有限公司 版權所有   技術支持:化工網   訪問量:4576  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |